Intro

This chapter discusses the FDA's recent decision to abolish the clozapine REMS program and its implications for both clinicians and patients. It emphasizes the reduced risks after the first year of treatment and explores new monitoring practices and the importance of patient education.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app